{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:41:38Z","timestamp":1790095298873,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Radiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacr.2026.03.017","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:08:56Z","timestamp":1777590536000},"page":"1235-1243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Shifts in Urbanicity-Based Access to Radiotracers for Neuroendocrine Tumors"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1666-6566","authenticated-orcid":false,"given":"Cindy X.","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie C.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-1102","authenticated-orcid":false,"given":"Elizabeth Y.","family":"Rula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-0787","authenticated-orcid":false,"given":"Eric W.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacr.2026.03.017_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jacr.2026.03.017_bib2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacr.2026.03.017_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate Use Criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jacr.2026.03.017_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"issue":"Suppl 1","key":"10.1016\/j.jacr.2026.03.017_bib5","first-page":"2038","article-title":"Ga-68 Dotatoc versus In-111 Ocreotide","volume":"60","author":"Coffey","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jacr.2026.03.017_bib6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2967\/jnumed.115.165803","article-title":"68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"57","author":"Deppen","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jacr.2026.03.017_bib7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-DOTATATE peptide receptor radionuclide therapy","volume":"61","author":"Hope","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jacr.2026.03.017_bib8","first-page":"426","article-title":"The value of (68)Ga-DOTATATE PET\/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature","volume":"4","author":"Mojtahedi","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jacr.2026.03.017_bib9","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2967\/jnumed.119.236091","article-title":"(64)Cu-DOTATATE PET\/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial","volume":"61","author":"Delpassand","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jacr.2026.03.017_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2967\/jnumed.120.244509","article-title":"(64)Cu-DOTATATE PET in patients with neuroendocrine neoplasms: prospective, head-to-head comparison of imaging at 1 hour and 3 hours after injection","volume":"62","author":"Loft","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jacr.2026.03.017_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2967\/jnumed.116.180430","article-title":"Head-to-head comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET\/CT: a prospective study of 59 patients with neuroendocrine tumors","volume":"58","author":"Johnbeck","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jacr.2026.03.017_bib12","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/cncr.29338","article-title":"Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: a population-based analysis of 6271 cases","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jacr.2026.03.017_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacr.2012.05.005","article-title":"Geographic and sociodemographic disparities in PET use by Medicare beneficiaries with cancer","volume":"9","author":"Onega","year":"2012","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.jacr.2026.03.017_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/diagnostics11020334","article-title":"Cost-effectiveness analysis of (68)Ga DOTA-TATE PET\/CT, (111)In-pentetreotide SPECT\/CT and CT for diagnostic workup of neuroendocrine tumors","volume":"11","author":"Froelich","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jacr.2026.03.017_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.119.233015","article-title":"Improving contrast and detectability: imaging with [(55)Co]Co-DOTATATE in comparison with [(64)Cu]Cu-DOTATATE and [(68)Ga]Ga-DOTATATE","volume":"61","author":"Andersen","year":"2020","journal-title":"J Nucl Med"}],"container-title":["Journal of the American College of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1546144026001699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1546144026001699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:32:35Z","timestamp":1782804755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1546144026001699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1546144026001699"],"URL":"https:\/\/doi.org\/10.1016\/j.jacr.2026.03.017","relation":{},"ISSN":["1546-1440"],"issn-type":[{"value":"1546-1440","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shifts in Urbanicity-Based Access to Radiotracers for Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacr.2026.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}